Abstract

Since antiquity, humans have sought the healing powers of sunshine to resolve many illnesses and restore a sensation of health and wellness. In recent publications, it has been reported that biophotonic treatment resulted in improvements in hemoglobin A1c and SpO2 concentrations in human subjects. In an animal study in which biophotonic treatment was applied to skeletal muscle in two models of Type 2 diabetes (NIDDM/T2DM), biophotonic treatment resulted in normalization of fasting and response plasma glucose concentrations and in an improvement in glycogen synthesis in skeletal muscle, likely secondary at least in part to improved GLUT4 actions and insulin sensitivity resulting in improved peripheral glucose uptake and oxidation and by increases in ATP generation in skeletal muscle. Because the biochemical mechanisms of carbohydrate metabolism and their contributions to the development of NIDDM are similar in both humans and in the animal models studied, the question arises as to whether biophotonic therapy might undergo consideration as an adjunct in the treatment of hyperglycemia, elevated HbA1c, peripheral oxygen delivery and wound healing in clinical management of NIDDM/T2DM. Biophotonic therapies have been widely used in the treatment of various infectious diseases and as an adjunct in antiaging medicine, but the observations on parameters of intermediary metabolism in humans and animal models of NIDDM/T2DM reflect new findings believed to be of significant importance if applied to the clinical management of obesity, NIDDM and impaired glycemic states in humans.

Keywords

obesity, Type 2 diabetes, NIDDM, glycemia, HbA1c, pO2